CX-Se13
CX-Se13 is an orally active pulmonary fibrosis inhibitor with anti-inflammatory and antioxidant activities. CX-Se13 regulates the Keap1/Nrf2/HO-1/NQO1, YAP/TAZ-TEAD, NF-κB p65 and TGF-β/Smads signaling pathways. CX-Se13 activates the cellular antioxidant defense system, restores redox balance, alleviates inflammatory responses, reduces collagen deposition, decreases pro-inflammatory cytokine levels and inhibits pathological progression. CX-Se13 can be used in studies related to pulmonary fibrosis.
For research use only. We do not sell to patients.
- Formula: C29H38N4O4Se
- Molecular Weight:585.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All YAP Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
YAP/TAZ-TEAD |
Smad3 |
p65 |
IL-1β |
IL-6 |
TNF-α |
In Vitro
CX-Se13 (compound E13) exhibits anti-inflammatory, antioxidant and antifibrotic activities, with an NO IC50 of 3.4 μM, an ROS inhibition rate of 93.4%, an α-SMA inhibition rate of 85.4%, and a cytotoxicity IC50 >100 μM[1].
CX-Se13 (1.25-20.0 μM) inhibits LPS-induced production of proinflammatory cytokines in RAW264.7 macrophages in vitro in a concentration-dependent manner[1].
CX-Se13 (10.0 μM) ameliorates TGF-β1-induced oxidative stress in MRC-5 fibroblasts by reducing ROS and MDA levels and increasing SOD levels[1].
CX-Se13 (0.625-40 μM; 24-72 h) inhibits TGF-β1-induced proliferation of MRC-5 fibroblasts in a time-dependent manner, with its IC50 value decreasing from 3.4 μM at 24 h to 0.9 μM at 72 h[1].
CX-Se13 (2.5-10.0 μM; 24 h) inhibits TGF-β1-induced migration of MRC-5 fibroblasts [1].
CX-Se13 (2.5-10.0 μM) reduces the expression of fibrosis markers in TGF-β1-induced MRC-5 fibroblasts in a concentration-dependent manner in vitro, and its antifibrotic activity is superior to that of PFD at equivalent doses; it activates the TGF-β1-induced Keap1/Nrf2/HO-1 pathway in MRC-5 fibroblasts and restores cellular redox balance[1].
CX-Se13 exhibits moderate permeability in Caco-2 cells, with a Papp value of 1.8 × 10-6 cm/s[1].
CX-Se13 directly binds to intracellular ROCK2 in living cells[1].
CX-Se13 (2.5-10.0 μM) dose-dependently inhibits the TGF-β1-induced NF-κB p65/IκBα pathway in MRC-5 fibroblasts in vitro. It also inhibits the TGF-β1/Smad pathway and reduces the expression of proteins related to collagen deposition, as well as suppresses the YAP/TAZ-TEAD pathway, thereby inhibiting fibroblast activation and extracellular matrix deposition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TGF-β1-stimulated MRC-5 fibroblasts
-
Concentration:0.625, 1.25, 2.5, 5, 10, 20, 40 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Inhibited TGF-β1-induced MRC-5 cell proliferation with IC50 values of 3.4 μM (24 h), 2.6 μM (48 h), and 0.9 μM (72 h), showing a time-dependent reduction in required drug dosage.
-
Cell Line:TGF-β1-stimulated MRC-5 fibroblasts
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Effectively reversed TGF-β1-induced abnormal migration of MRC-5 cells, with inhibitory effects comparable to positive control pirfenidone (PFD) at the same dose.
Parmacokinetics
In Vivo
CX-Se13 (10-40 mg/kg; intragastric administration once daily for 14 consecutive days starting from day 7 of modeling) dose-dependently ameliorates systemic and respiratory abnormalities in mice with bleomycin (HY-108345)-induced pulmonary fibrosis, alleviates pulmonary hemorrhage, alveolar injury, collagen deposition and inflammatory infiltration, and downregulates fibrosis markers and inflammatory cytokines; it also activates the Nrf2 antioxidant pathway and inhibits the pro-inflammatory and pro-fibrotic NF-κB, TGF-β/Smad, and YAP/TAZ pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice[1]
-
Dosage:500 mg/kg
-
Administration:p.o.; daily; 5 days
-
Result:Observed no mortality, toxic symptoms, lethargy, or significant body weight loss over a 12-day experimental cycle.
Detected no obvious histopathological changes in heart, liver, spleen, lung, or kidney tissues via H&E staining.
-
Animal Model:Male C57BL/6 mice were intratracheally instilled with Bleomycin (2 mg/kg) to construct pulmonary fibrosis model, Pirfenidone (HY-B0673) (100 mg/kg) was set as positive control[1]
-
Dosage:10, 20, 40 mg/kg
-
Administration:Intragastric administration; once daily for 14 days starting from day 7 after modeling
-
Result:Alleviated weight loss, lethargy and dyspnea in a dose-dependent manner, restored lung elasticity and reduced pulmonary hemorrhagic foci and fibrous scars.
Relieved alveolar destruction, alveolar septal thickening and inflammatory infiltration observed in H&E staining; lowered collagen fiber deposition displayed by Masson staining.
Downregulated the expression of α-SMA, Collagen I, Collagen III and Fibronectin in lung tissues, and decreased serum hydroxyproline content.
Reduced concentrations of TNF-α, IL-1β and IL-6 in serum and bronchoalveolar lavage fluid (BALF).
Activated Keap1/Nrf2/HO-1/NQO1 signaling axis, inhibited phosphorylation of NF-κB p65/IκBα, blocked TGF-β/Smad2/3 pathway activation and suppressed YAP/TAZ-TEAD4 fibrotic signaling in lung tissues.
Chemical Information
-
Molecular Weight 585.60
-
Formula C29H38N4O4Se
-
SMILES
O=C(NC1CCC(OC)CC1)C2=CC3=CC(C4=CN(C5CCN(C(OC(C)(C)C)=O)CC5)N=C4)=CC=C3[Se]2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)